Parter

Exoxemis is focused on the development of haloperoxidase enzyme-based products to address the increasing threat of serious and drug-resistant infections. We are committed to:

• Leveraging expertise in enzymology, bioanalytical methods, microbiology,
  and formulation sciences to bring new products to market.
• Applying highest quality science, research, and development to our
  partnerships and collaborations.
• Supporting scholarship and innovation in evolving applications of
  our technology.
• Targeting product opportunities to address areas of high, unmet clinical
  demand, and strong potential market growth.
• Extending the application of the myeloperoxidase and eosinophil peroxidase
  technology platform to a wide variety of medical, veterinary, agricultural,
  disinfectant, and industrial applications.
• Offering flexibility in formulation to accommodate multiple indications
  and provide a cGMP-manufactured product
• Delivering value to partners and collaborators.